Loading
journalsJournal
JAMA Internal Medicine
JAMA Internal Medicine is the JAMA Network's internal-medicine journal, known for sceptical, evidence-based analyses of overdiagnosis, surrogate endpoints and low-value care in cancer.
Also called: JAMA Intern MedArchives of Internal Medicine
Overview
JAMA Internal Medicine was formerly Archives of Internal Medicine (renamed 2013). It is home to the 'Less Is More' series and of influential critiques of oncology evidence, including Prasad and colleagues' 2015 review of surrogate endpoints in cancer drug approvals, plus prevention studies such as the PREDIMED breast-cancer analysis. Hybrid access.
Publisher
American Medical Association (JAMA Network) · American Medical Association
Scope
general medicine
Access model
hybrid
Founded
1908
ISSN
2168-6106
Impact factor (2023)
22.5 · Clarivate Journal Citation Reports 2024 (2023 JIF)
review2019222 citations
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational2015changed practice
Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk
The reason cardiac surveillance belongs in Hodgkin lymphoma survivorship care, the reason smoking cessation is a specific intervention for this group rather than general advice, and part of the reason modern protocols try to limit both mediastinal radiation and cumulative anthracycline dose.
meta analysis2015312 citations
Prasad: most surrogate endpoints in cancer trials correlate poorly with survival
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
rct2015341 citations
PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers
A Mediterranean dietary pattern rich in olive oil may lower breast cancer risk, and it is safe and good for the heart anyway. The evidence is suggestive, not definitive, because of the small number of cancers; it should not be presented as proven cancer prevention.
Christopher M. Booth
Professor of Oncology and Public Health Sciences, Queen's University; Medical Oncologist, Kingston Health Sciences Centre
Cancer policy and evidenceCommon Sense OncologyHealth services research
Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients.
Ian F. Tannock
Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto
Trial methodologyProstate cancerClinical benefit assessment
Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.
Joseph S. Ross
Professor of Medicine (General Medicine) and of Public Health (Health Policy)
Drug regulationClinical trial transparencyHealth policy
Yale health policy researcher on the YODA Project leadership team, known for work on FDA regulation and trial transparency.
Michael Bretthauer
Professor of Medicine, University of Oslo; Gastroenterologist, Oslo University Hospital
Colorectal cancer screeningColonoscopy trialsScreening epidemiology
Led NordICC, the first randomised trial of screening colonoscopy, which found smaller benefits than many expected.
reviewJAMA Internal Medicine 2019222 citations
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalJAMA Internal Medicine 2015changed practice
Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk
The reason cardiac surveillance belongs in Hodgkin lymphoma survivorship care, the reason smoking cessation is a specific intervention for this group rather than general advice, and part of the reason modern protocols try to limit both mediastinal radiation and cumulative anthracycline dose.
meta analysisJAMA Internal Medicine 2015312 citations
Prasad: most surrogate endpoints in cancer trials correlate poorly with survival
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
rctJAMA Internal Medicine 2015341 citations
PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers
A Mediterranean dietary pattern rich in olive oil may lower breast cancer risk, and it is safe and good for the heart anyway. The evidence is suggestive, not definitive, because of the small number of cancers; it should not be presented as proven cancer prevention.
Similar pages
- TrialTMIST (Tomosynthesis Mammographic Imaging Screening Trial)
Shares Overdiagnosis, Screening.
- Key paperManagement and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE
Shares Overdiagnosis, Screening.
- Key paperOutcomes of Gallbladder Polyps and Their Association With Gallbladder Cancer in a 20-Year Cohort
Shares Overdiagnosis, Screening.
- TechnologySkin cancer screening (visual skin examination)
Shares Overdiagnosis, Screening.
- Key paperUSPSTF 2012: screening for prostate cancer, recommendation statement (grade D)
Shares Overdiagnosis, Screening.
- IdeaRisk-targeted ultrasound screening in high-incidence regions, tested against usual care
Shares Overdiagnosis, Screening.
- TermGallbladder polyp (polypoid lesion)
Shares Overdiagnosis, Screening.
- Key paperProstate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005
Shares Overdiagnosis, Screening.
terms
people
key papers
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated ApprovalCardiovascular disease after Hodgkin lymphoma treatment: 40-year disease riskPrasad: most surrogate endpoints in cancer trials correlate poorly with survivalPREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers